Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 3/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21528786 | 0.85 | MMP2 (0.42) | PPARGPPARACCR2PSEN1PSEN2 | |
| SCHEMBL21528784 | 0.85 | MMP2 (0.42) | PPARGPPARACCR2PSEN1PSEN2 | |
| SCHEMBL21528749 | 0.84 | PPARG (0.41) | KLK5PPARGPPARACTSSCTSK | |
| SCHEMBL21528752 | 0.84 | PPARG (0.41) | KLK5PPARGPPARACTSSCTSK | |
| SCHEMBL27449230 | 0.83 | PPARG (0.51) | KLK5PPARGPPARACTSSCTSK | |
| SCHEMBL9922080 | 0.83 | PPARG (0.51) | KLK5PPARGPPARACTSSCTSK | |
| SCHEMBL12056576 | 0.83 | PPARG (0.51) | KLK5PPARGPPARACTSSCTSK | |
| SCHEMBL21549320 | 0.81 | MMP2 (0.46) | PPARGPPARACTSSCTSKMMP2 | |
| SCHEMBL21549384 | 0.81 | PPARG (0.49) | PPARGPPARACTSSCTSKMMP2 | |
| SCHEMBL8894363 | 0.80 | PSEN1 (0.52) | KLK5PPARGPPARACTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384060-B2 | Amide compounds and use thereof | ALPHALA CO., LTD. (TW) | 2022-07-12 | — | — | US | disclosed |
| US-11384060-B2 | Amide compounds and use thereof | ALPHALA CO., LTD. (TW) | 2022-07-12 | — | — | US | disclosed |
| US-20190337915-A1 | AMIDE COMPOUNDS AND USE THEREOF | ALPHALA CO., LTD. (TW) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337915-A1 | AMIDE COMPOUNDS AND USE THEREOF | GLP1R, IAPP, GPR119 | KLK5 1015/4885PPARG 93/4885PPARA 161/4885 |
| US-11384060-B2 | Amide compounds and use thereof | GLP1R, IAPP, GPR119 | KLK5 1015/4885PPARG 93/4885PPARA 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.